RTGN · RetinalGenix Technologies Inc.
$4.00
At close · May 4
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$75.37M
Shares
18.84M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$2.43M
+43.8%
FY2025
Diluted EPS
-$0.13
+45.8%
FY2025
Operating Cash Flow
-$558.35K
+24.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $238.87K | $83.04K | $373.27K | $524.18K | $809.26K | $680.29K | $431.56K | |
| $1.05M | $1.3M | $1.33M | $898.66K | $807.41K | $1.12M | $1.43M | |
| $2.08M | $2.42M | $4.32M | $2.09M | $3.91M | $2.18M | $2.08M | |
| — | — | — | — | $79.29K | $68.07K | $127.97K | |
| $7241 | $4005 | $3840 | $3840 | $5140 | $2619 | — | |
| -$2.09M | -$2.43M | -$4.32M | -$2.09M | -$3.91M | -$2.18M | -$2.08M | |
| USD/shares | -$0.12 | -$0.13 | -$0.24 | -$0.12 | -$0.25 | -$0.05 | — |
| USD/shares | -$0.12 | -$0.13 | -$0.24 | -$0.12 | -$0.25 | — | — |
| shares | — | 18.56M | 17.94M | 17.35M | 15.58M | 41.25M | 39.7M |
| shares | — | 18.56M | 17.94M | 17.35M | 15.58M | 41.25M | 39.7M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.72×
EV/EBIT
—
Peer median 16.67×
P/E (TTM)
—
Peer median 24.50×
Peer medians compare against the 70 similar-size Medical Devices companies (of 144 listed).